Stay in Touch!

Mucosal Immunity Innovation
( MucInn) Teaming

Thank you for your interest in the Mucosal Immunity Innovation (MucInn) Program. MucInn is seeking to advance formulation and delivery technologies for mucosal influenza vaccines that can effectively deliver vaccines in relevant nonclinical models. Areas of interest include technologies that enhance penetration across mucosal surfaces, overcome mucosal delivery barriers, elicit robust and durable mucosal and systemic immune responses, co-deliver antigen and adjuvant, and improve translational readiness and manufacturability. Because these goals often require multidisciplinary expertise, collaborations between innovators are encouraged to strengthen potential applications.

Teaming

If you or your organization would like to explore collaborations with other potential MucInn applicants, please complete the form below. Following a brief vetting process, VITAL will contact you and, if approved, add your information to a publicly accessible teaming directory to help facilitate connections with prospective collaborators. This directory is intended to bring together organizations with complementary expertise, including mucosal vaccine development, antigen design, delivery technologies, adjuvants and formulations, influenza pathophysiology, vaccine development and regulatory strategy, manufacturing, and influenza immunogenicity and challenge studies.

Submit Teaming Form

Browse profiles of organizations and researchers interested in MucInn collaboration below. Each profile includes contact information, so if you see a potential fit, reach out directly to start the conversation. VITAL does not broker individual partnerships, so we encourage you to connect with collaborators on your own.

Please note that by publishing the teaming profiles, neither VITAL nor BARDA is endorsing, sponsoring, or otherwise promoting or elevating the qualifications of the individuals or organizations included on the list. Additionally, completing the teaming form does not constitute an application for the MucInn funding opportunities, but rather, provides you an opportunity to partner and collaborate with other potential applicants to strengthen the quality of the submission. Submissions to the teaming profiles list are reviewed and updated periodically. 

Boost Biopharma, Inc.

Last updated:
Contact
Steve Gold
Location
Boston, MA, United States
Website
https://www.boostbiopharma.com/
Organization Type
  • Biotech
Core Development Category
  • Antigen/Vaccine development
Technology Category
  • Antigen-adjuvant co-delivery
Current Stage of Development
  • Clinical stages

Primary Focus of Work

Boost's focus: novel protein subunit antigen platforms

Influenza Vaccine Delivery in Nonclinical Models

Boost's influenza antigens have been evaluated in NHPs, and the Rapid Vaccine Antigen (RVA) platform is clinically demonstrated.

What We’re Seeking in Teaming Partners

Boost is seeking partners with adjuvant and other technologies that could improve intranasal administration effectiveness of our protein subunit antigens. Boost's influenza antigens (non-adjuvanted) have already been demonstrated as safe and effective in NHPs, and we are seeking partners to further improve our vaccine performance.

Codagenix Inc

Last updated:
Contact
Jeffrey Fu
Location
Farmingdale, NY, United States
Website
https://www.codagenix.com
Organization Type
  • Biotech
Core Development Category
  • Antigen/Vaccine development
Technology Category
  • Other
Current Stage of Development
  • Clinical stages

Primary Focus of Work

2nd generation pandemic and seasonal live virus influenza vaccines

Influenza Vaccine Delivery in Nonclinical Models

Intranasal delivery demonstrated HAI and nAb responses in small and NHP animal models

What We’re Seeking in Teaming Partners

Deep and consistent intranasal upper respiratory tract delivery of live attenuated influenza vaccines

TollereBio

Last updated:
Contact
Hans Lien
Location
Silver Spring, MD, United States
Website
https://www.tollerebio.com
Organization Type
  • Biotech
Core Development Category
  • Adjuvant & immune modulation
Technology Category
  • Mucosal adjuvants
Current Stage of Development
  • Pre-clinical

Primary Focus of Work

Vaccine adjuvants

Influenza Vaccine Delivery in Nonclinical Models

Published data available for the use of BECC adjuvants in influenza pre-clinical models

What We’re Seeking in Teaming Partners

TollereBio’s BECC adjuvant technology platform offers best in class, rationally designed TLR4 agonist adjuvants backed by pre-clinical data demonstrating the ability to elicit balanced Th1/Th2 immune responses, promote cross-protective immunity, enhance vaccine durability, and enable dose sparing. Our lead adjuvants BECC470s and BECC438s are fully synthetic, with structure specific purity and clear regulatory pathways for clinical development.